Document is current
Any future updates will be listed below
-
Authors
Bakker, Noor A. M. https://orcid.org/0000-0002-7167-581X
Garner, Hannah
van Dyk, Ewald
Champanhet, Elisa
Klaver, Chris
Duijst, Maxime
Voorwerk, Leonie
Nederlof, Iris https://orcid.org/0000-0001-7608-6515
Voorthuis, Rosie
Liefaard, Marte C.
Nieuwland, Marja
de Rink, Iris
Bleijerveld, Onno B. https://orcid.org/0000-0002-9395-2347
Oosterkamp, Hendrika M.
Wessels, Lodewyk F. A. https://orcid.org/0000-0002-1656-6995
Kok, Marleen https://orcid.org/0000-0001-9043-9815
de Visser, Karin E. https://orcid.org/0000-0002-0293-868X
-
Funding
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWOVICI91819616)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWOVIDI09150172010043)
KWF Kankerbestrijding (KWF13191)
KWF Kankerbestrijding (KWF14801)
X-omics Initiative
Victoria’s Secret Global Fund for Women’s Cancers Rising Innovator Research Grant, in Partnership with Pelotonia & AACR. A Sister’s Hope foundation.
- License Information
-
More Information
Article History
Received: 18 July 2024
Accepted: 9 January 2025
First Online: 23 January 2025
Competing interests
: N.A.M.B., E.v.D., H.G., E.C., C.K., M.D., L.V., I.N., R.V., M.L., M.N., I.d.R., and O.B. have no conflicts of interest to declare. H.M.O. reports funding to the institute from Roche in order to perform the Triple B study and an advisory board fee from Novartis, Pfizer, Gilead, AstraZeneca, and Daiichi Sankyo outside the submitted work. L.F.A.W. reports funding to the institute from Genmab BV. M.K. reports funding to the institute from BMS, Roche/ Genentech, AZ, and an advisory role/speakers fee for Alderaan, BMS, Domain Therapeutics, Gilead, Roche, MSD, and Daiichi Sankyo, outside the submitted work. K.E.d.V. reports research funding from Roche/Genentech and is a consultant for Macomics, outside the scope of this work.
